C

테고사이언스

191420KOSDAQ

41.3 / 100

Reference Date: 2026-09-08

Financial Score13.0 / 40
News Sentiment11.3 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 13.4% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Tegos Science specializes in developing and producing cell therapy products using advanced cell culture technology, alongside offering contract manufacturing, consulting, and quality management services. The company has commercialized a 3D cultured skin model, NeoDerm®, for animal alternative testing and drug screening. The global cell therapy market is projected to grow from $4.2 billion in 2023 to $7.8 billion by 2028, with Tegos holding three approved cell therapy products in South Korea, including treatments for burns, diabetic foot ulcers, and wrinkle improvement.

Number of Employees

40people

Average Salary

48.0M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 15.004.0Point
PBR
1.21Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE
-14.04Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
47.88Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼12.6% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼93.1% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -4.0% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 0Negative 1Average Sentiment Score 45

Detailed Momentum

52-week position1.0Point

Near 52w low (14%, downtrend)

Current 7,540Won52-week high 18,97052-week low 5,600
1-month return5.0Point

1m +13.38% (rising)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0
  • Neutral임원ㆍ주요주주특정증권등거래계획보고서2026-08-18
  • Neutral반기보고서 (2026.06)2026-08-14